| Identification | Back Directory | [Name]
CTCE 9908 | [CAS]
1030384-98-5 | [Synonyms]
CTCE 9908
CTCE 9908 TFA
N2,N6-Bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-L-lysinamide
L-Lysinamide, N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)- | [Molecular Formula]
C86H147N27O23 | [MDL Number]
MFCD27991298 | [MOL File]
1030384-98-5.mol | [Molecular Weight]
1927.25 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Powder | [color ]
White to off-white | [Sequence]
Sequence 1:Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg-Lys-NH2;Sequence 1':Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg (Amide bridge:Lys9-Arg8’) |
| Hazard Information | Back Directory | [Uses]
CXCR4 is a chemokine receptor often overexpressed in cancer cells and involved with metastasis. N2,N6-Bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-L-lysinamide is a CXCR4 antagonist. It inhibits ovarian cancer cell migration to CXCL12 and induces cell death in CXCR4-positive cells. | [in vivo]
CTCE-9908 (25, 50 and 100 mg/kg; s.c.; 5 days per week for 4.5 weeks) alone slows the rate of primary breast tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg in FVB/N TgN (MMTV-PyMT)634 male mice[2].
| [IC 50]
CXCR4 | [storage]
Store at -20°C |
|
|